Recent patents therapeutic agents for cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 2, 2006, Pages 255-284

  Li, Xun ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Analogs; Anthracycline; Anti tumor; Anticancer; Application; Camptothecin; Derivatives; Pharmaceutical combinations; Platinum complex; Podophyllotoxins; Preparation; Quinoline; Taxane; Therapeutic agents

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX; PODOPHYLLOTOXIN; TAXOID;

ANIMAL; HUMAN; NEOPLASM; PATENT; REVIEW;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PATENTS AS TOPIC; PODOPHYLLOTOXIN; TAXOIDS;

EID: 33748539402     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206777442188     Document Type: Review

References (145)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics 2000, CA. Cancer J Clin 2000; 50:7-33.
2. Cai ZX, Gan RF. Market analysis for anticancer drugs. World Clin Drugs 2004; 25(5): 1-4.
3. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 2001; 19(10): 940-5.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Oliver RT. Testicular cancer. Curr Opin Oncol 1994; 6: 285-91.
6. 3Cl]Cl, where L = 3-hydroxypyridine, 4-hydroxypyridine and imidazo(1,2-)pyridine. J Inorg Biochem 2005; 99(5): 1098-112.
7. Lakomska I, Golankiewicz B, Wietrzyk J, et al. Synthesis, spectroscopical characterization and the biological activity in vitro of new platinum(II) complexes with imidazo[1,5-a]-1,3,5-triazine derivatives and dimethylsulfoxide. Inorg Chim Acta 2005; 358(6): 1911-7.
8. 2O. J Inorg Biochem 2005; 99(3): 795-804.
9. Jin VX, Tan SI, Ranford JD. Platinum (II) triammine antitumour complexes: structure-activity relationship with guanosine 5́-monophosphate (5́-GMP). Inorg Chim Acta 2005; 358(3): 677-86.
10. Kelland LR, Mckeage MJ. Platinum drugs currently in clinical trial. Curr Opin Invest Drugs 1993; 2: 571-80.
11. Weiss RB, Christian MC. New cis-platin drugs in development. Drugs 1993; 46: 360-77.
12. Pérez JM, Fuertes MA, Alonso C, Navarro-Ranninger C. Current status of the development of trans-platinum antitumor drugs. Crit Rev Oncol/Hematol 2000; 35: 109-20.
13. Adams M, Calvert AH, Carmichael J, et al. Chemotherapy for ovarian cancer-a consensus statement on standard practice. Br J Cancer 1998; 78 (11): 1404-6.
14. Margiotta N, Habtemariam A, Sadler PJ. Strong, rapid binding of a platinum complex to thymine and uracil under physiological conditions. Angew Chem 1997; 36 (11): 1185-7.
15. 2. ZAAC 2002; 628 (5): 1075-84.
16. Zou, J.: CN1120544A (1996).
17. Koichi, Y., Kinichi, M., Hidehiko, K.: CN1116206A (1996).
18. Yokoi, K., Shigeki, K., Kotani, H.: CN1133293A (1996).
19. Valsecchi, M., Conti, M., Del Greco, L.: CN1145624A (1997).
20. Xiuwen, H., Xinning, W., Tao, J.: CN1197798A (1998).
21. Xiuwen, H., Xinning, W., Lie, C.: CN1197799A (1998).
22. Dae-Kee, K., Sang-Hyeok, K., Jong-Sik, G.: CN1204650A (1999).
23. Xiuwen, H., Jingzun, W.: CN1314357A (2001).
24. Xuqing, Y., Zhenyun, Y., Yingwu, Y.: CN1311183A (2001).
25. Teni, B.: CN1343118A (2002).
26. Shaohua, G., Yongjiang, C.: CN1339439A (2002).
27. Shaohua, G., Yun, L.: CN1569862A (2005).
28. Zijian, G., Xiaoyong, W., Junyong, Z.: CN1448389A (2003).
29. Shaohua, G., Lianhong, W.: CN1478785A (2004).
30. Shaoping, P., Zebing, Z., Chuanzhu, G.: CN1557822A (2004).
31. Shaoping, P., Xuejie, L., Zhudong, L.: CN1557825A (2004).
32. Dexian, D.: CN1557823A (2004).
33. Farrell N, Qu Y, Roberts JD. In: Topics in biological inorganic chemistry. Vol 1, Springer, Berlin 1999; 99-115.
34. Arcamone F. In: de Stevens. G Ed, Doxorubicin, anticancer antibiotics in medicinal chemistry series. Academic press, New York.1981; 1-369.
35. Wei SH. Current research of anthracycline analogs as anticancer drugs. Med Sci Abroad/Oncol 2000; 26(5): 288-300.
36. Capranico G, Butelli E, Zunino F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA clearage by epimerization of the amino group of the sugar moiety. Cancer Res 1995; 55: 312-7.
37. Fabio, A., Federico, A.K.J.: CN1154701A (1997).
38. Sakurai, Y., Yokoyama, M., Kataoka, K.: CN1165518A (1997).
39. Zhang, X., Olson, R.D., Walsh, G.M.: CN1270522A (2000).
40. Geroni, C., Ripamonti, M., Caruso, M.: CN1263532A (2000).
41. Schally, A.V., Nagy, A.A., Cai, R.Z.: CN1202903A (1998).
42. Shangli, C.: CN1320605A (2001).
43. Perez-Baz, J., Canedo, L.M., Garcia, G.D.: CN1449399A (2003).
44. Xushan, H., Rongfu, C.: CN1504453A (2004).
45. Lianquan, L.G.: CN1546451A (2004).
46. Rommelspacher H, May T, Susilo R. β-carbolines and tetrahydroisoquinolines: detection and function in mammals. Planta Med 1991; 57(7): S85-S92.
47. Shimizu, H., Abe, A., Yaegshi, T.: CN1141633A (1997).
48. Yoshikazu, J., Tomohiro, M., Yoshiaki, I.: CN1145361A (1997).
49. Barker, A.J., Johnstone, C.: CN1211240A (1999).
50. Wissner, A., Tsou, H.-R., Berger, D.M.: CN1320121A (2001).
51. Lagreca, S.D., Lyssikatos, J.P.: CN1314904A (2001).
52. Peigen, X., Guangyue, G., Junshan, Y.: CN1267670A (2000).
53. Husson, H.-P., G-Lenorter, S., Tratrater, C.: CN1302804A (2001).
54. Fengpeng, W., Li, W., Jinsong, Y.: CN1293196A (2001).
55. Yang, B.: CN1340051A (2002).
56. Takeuchi, T., Umezawa, S., Tsuchiya, T.: CN1341117A (2002).
57. Kubo, K., Fujiwara, Y., Isoe, T.: CN1344254A (2002).
58. Zhihong, L.: CN1314351A (2001).
59. Boschelli, D.H., Wang, Y., Boschelli, F.C.: CN1419545A (2003).
60. Husson, H.P., Renault, S.G., Desbene, S.: CN1511158A (2004).
61. Birnberg, G.H., Wang, Y., Berger, D.M.: CN1483019A (2004).
62. Fujiwara, Y., Hasegawa, K., Isoue, T., Kubo, K., Nagao, R., Sakai, T.: CN1543459A (2004).
63. Samizu, K., Hisamichi, H., Matsuhisa, A.: CN1511151A (2004).
64. Fujiwara, Y., Nakamura, K., Miwa, A., Osawa, T., Senga, T., Nishitoba, T.: CN1553899A (2004).
65. Hennequin, L.F. A, Kettle, J.G., Pass, M., Bradbury, R.H.: CN1585754A (2005).
66. Lianquan, Z.G.: CN1546473A (2004).
67. Gang, L., Baoan, S., Song, Y.: CN1597671A (2005).
68. Ward RS. The synthesis of ligants and neolignants. Chem Soc Rev 1982; 11: 75-125.
69. Sudo K, Konno K, Shigeta S, Yokota T. Inhibitory effects of podophyllotoxin derivatives on herpes simplex virus replication. Antivir Chem Chemother 1998; 9: 263-7.
70. Syed TA, Cheema KM, Khayyami M, Ahmad SA, Ahmad SH, Ahmad S. Human leukocyte interferon-aversus podophyllotoxin in cream for the treatment of genital warts in males. A placebo-controlled, double-blind, comparative study. Dermatology 1995; 191: 129-32.
71. MacRae WD, Hudson JB, Towers GH. The antiviral action of lignans. Planta Med 1989; 55: 531-5.
72. Subrahmanyam D, Renuka B, Rao CV, Sagar PS, Deevi DS, Babu JM, Vyas K. Novel D-ring analogs of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett 1998; 8: 1391-6.
73. Subrahmanyam D, Renuka B, Kumar GS, Vandana V, Deevi DS. Deoxopodophyllotoxin derivatives as anti-cancer agents. Bioorg Med Chem Lett 1999; 9: 2131-4.
74. Pugh NI, Khan I, Moraes RM, Pasco D. Podophyllotoxin lignans enhance IL-1E but suppress TNF-a mRNA expression in LPS-treated monocytes. Immunopharmacol Immunotoxicol 2001; 23: 83-95.
75. Oliva A, Moraes RM, Watson SB, Duke SO, Dayan FE. Aryltetralin lignans inhibit plant growth by affecting the formation of mitotic microtubular organizing centers. Pestic Biochem Physiol 2002; 72: 45-54.
76. Monneret, C., Daley, L., Gumiski, Y.: CN1202173A (1998).
77. Weiyong, M., Zaixin, C., Chunnian, Z.: CN1331078A (2002).
78. Weiyong, M., Zaixin, C., Chunnian, Z.: CN1303855A (2001).
79. Shaoming, C.: CN1379028A (2002).
80. Shaoming, C.: CN1371909A (2002).
81. Shaoming, C.: CN1410425A (2003).
82. Ahn, B.-Z., Kim, Y., You, Y.-J.: CN1474822A (2004).
83. Shaoming, C.: CN1566115A (2005).
84. Shiqiang, C., Xuan, T., Yongqiang, T.: CN1563011A (2005).
85. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant anti-tumor agents: VI. The isolation and structure of taxol, a novel antileukemic and anti-tumor agent from Taxus brevifolia. J Am Chem Soc l971; 93: 2325-7.
86. Ma PQ. Clinical progress of paclitaxel. Chinese J Med Guide 2004; 6(3): 201-4.
87. Nabholtz JM, Riva A. Taxane/anthracycline combinations: setting a new standard in breast cancer. Oncologist 2001; 6: (Suppl. 3) 5-12.
88. Tarrant JG, Cook D, Fairchild C, et al. Synthesis and biological activity of macrocyclic taxane analogues. Bioorg Med Chem Lett 2004; 14: 2555-8.
89. Kelly, R.C., Wuts, P.G.M., Wicniensky, N.A.: CN1139925A (1997).
90. Bouchard, H., Bourzat, J.-D., Commercon, A.: CN1150422A (1997).
91. Bouchard, H., Bourzat, J.-D., Commercon, A.: CN1150423A (1997).
92. Bombardelli, E., DeBellis, P., Gabetta, B.: CN1154109A (1997).
93. Kelly, R.C., Gebhard, I.: CN1151740A (1997).
94. Pandey, R.C., Yankov, L.K., Nair, R.: CN1190964A (1998).
95. Terasawa, H., Soga, T., Ishiyama, T.: CN1188477A (1998).
96. Xioming, W., Jirong, Z.: CN1164533A (1997).
97. Grike, J., Weyas, D., Leit, J.J.: CN1174838A (1998).
98. Klar, U., Neff, G., Graf, H.: CN1210535A (1999).
99. Arnold, L.D.: CN1225633A (1999).
100. Liu, J.: CN1261360A (2000).
101. Abe, A., Shimizu, H., Sawada, S.: CN1270587A (2000).
102. Shimizu, H., Abe, A., Ogawa, T.: CN1286686A (2001).
103. Xioming, W.: CN1243125A (2000).
104. Bristol-Myers, S.C.: CN1237580A (1999).
105. Bombardelli, E., Gabetta, B., Pontiroli, A.: CN1359384A (2002).
106. Soga, T., Uoto, K., Takeda, Y.: CN1409714A (2003).
107. Holton, R.A.: CN1429225A (2003).
108. Holton, R.A.: CN1362955A (2002).
109. Holton, R.A.: CN1380882A (2002).
110. Horton, R.A.: CN1362957A (2002).
111. Holton, R.A.: CN1362956A (2002).
112. Horton, R.A.: CN1362876A (2002).
113. Horton, R.A., Fang, W.: CN1362959A (2002).
114. Bombardelli, E., Fontana, G., Battaglia, A.: CN1538841A (2004).
115. Fajun, N., Jia, L., Wei, L.: CN1513850A (2004).
116. Jianmin, J.C.: CN1523023A (2004).
117. Wall ME. In: Chronicles of drug discovery, Lednicer D Ed, American Chemical Society, Washington D.C. 1993; Vol 3, 327-8.
118. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives (Review). Bioorg Med Chem 2004; 12: 1585-1604.
119. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279(6): 1504-13.
120. Song LL, Zhang WN, Ji HT, et al. Flexible molecular docking studies of antineoplastic camptothecin derivatives on DNAtopoisomerase I complex. Acta Chim Sinica 2003; 61(11): 1860-6.
121. Uehling DE, Nanthakumar SS, Croom D, et al. Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs. J Med Chem 1995; 38(7): 1106-18.
122. Li Y, Tang Q, Dong L, Yin SF. Progress in research of structure modification and structure activity of camptothecin and its analogues. Chem Res Appl 2003; 15(6): 744-8.
123. Takashi, Y., Seigo, S., Tomio, F.: CN1126212A (1996).
124. Tsujihara, K., Kawaguchi, T., Okuno, T.: CN1145365A (1997).
125. Tsujihara, K., Kawaguchi, T., Okuno, T.: CN1158334A (1997).
126. Cabri, W., Candiani, I., Bedeschi, A.: CN1159192A (1997).
127. Asahina, Y., Oomori, Y.: CN1187195A (1998).
128. Jew, S.-S., Lee, H.-S., Kim, J.-K.: CN1168139A (1997).
129. Bigg, D., Lavergne, O., Plarodas, F.: CN1192740A (1998).
130. Duvvuri, S., Akella, V., Vedula, S.M.: CN1198164A (1998).
131. Cao, Z., Beppino, C.C.: CN1214686A (1999).
132. Merlini, L., Penco, S., Zunino, F.: CN1211987A (1999).
133. Hausheer, F.H., Haridas, K., Seetharamulu, P.: CN1227559A (1999).
134. Ogawa, T., Yaegashi, T., Sawada, S.: CN1278261A (2000).
135. Cazaux, J.-B., Lavergne, O., Le Breton, C.: CN1268948A (2000).
136. Tsujihara, K., Kawaguchi, T.: CN1308078A (2001).
137. Penco, S., Merlini, L., Zunino, F.: CN1343209A (2002).
138. Lavergne, O., Bigg, D., Lanco, C.: CN1345321A (2002).
139. Wei, L., Qin, Z., Junfang, P.: CN1465577A (2004).
140. Xiandao, P., Rui, H., Piaoyang, S.: CN1482128A (2004).
141. Xinyi, L., Yongmin, Z.: CN1534036A (2004).
142. Jinsheng, Z., Jun, C., Liguang, L.: CN1580057A (2005).
143. Wannian, Z., Song, Y., Jianzhong, Y.: CN1557814A (2004).
144. Bo, Y., Wei, L., Qiaojun, H.: CN1587265A (2005).
145. Jianli, L.: CN1597683A (2005).